LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor
Open Access
- 4 April 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 108 (9), 1765-1770
- https://doi.org/10.1038/bjc.2013.138
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor statusNeuro-Oncology, 2013
- The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor SuppressorCell, 2012
- Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signallingNature, 2012
- Lrig1 Is an Estrogen-Regulated Growth Suppressor and Correlates with Longer Relapse-Free Survival in ERα-Positive Breast CancerMolecular Cancer Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomesBMC Bioinformatics, 2010
- Lrig1 Expression Defines a Distinct Multipotent Stem Cell Population in Mammalian EpidermisCell Stem Cell, 2009
- Suppression of the Negative Regulator LRIG1 Contributes to ErbB2 Overexpression in Breast CancerCancer Research, 2008
- LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIIIOncogene, 2008
- LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 SynergyMolecular and Cellular Biology, 2007